Gossamer Bio Announces Seralutinib Rights Reacquisition, FDA Meeting Outcome, and Capital Structure Updates
Gossamer Bio, Inc. held a business update call to announce several key developments. The company reported the outcome of its pre-NDA Type B meeting with the FDA, including receipt of official minutes. It also announced the reacquisition of worldwide development and commercial rights to seralutinib from Chiesi. Additionally, stockholders approved proposals related to a convertible note exchange and a reverse stock split. The call featured remarks from CFO/COO Bryan Giraudo, with CEO Faheem Hasnain, Chief Development Officer Caryn Peterson, and Commercial Officer Bob Smith available for Q&A. The company emphasized forward-looking statements regarding its planned NDA submission, potential regulatory review and approval timing, and the anticipated benefits of the rights reacquisition.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection